Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Advanced BiomedADVB +40.11%12 Earnings per Share (Diluted) is $4.76 as of Mar. 2026. GuruFocus rates ADVB with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 159 Medical Diagnostics & Research companies, Advanced Biomed ranks worse than 98.74% on this metric.
Advanced Biomed's EPS (Basic) for the
three
months ended in Mar. 2026 was $-0.38.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was $4.76.
During the past 3 years, the average EPS without NRIGrowth Rate was -97.50% per year.
During the past 5 years, Advanced Biomed's highest 3-Year average EPS without NRI Growth Rate was -10.60% per year. The lowest was -97.50% per year. And the median was -54.05% per year.
Advanced Biomed (NAS:ADVB) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Advanced Biomed Earnings per Share (Diluted) Related Terms
Advanced Biomed Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for Advanced Biomed's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Advanced Biomed Earnings per Share (Diluted) Chart
ADVB vs MBAI, XWEL, NDRA: Earnings per Share (Diluted) Comparison
For the Diagnostics & Research subindustry, Advanced Biomed's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Advanced Biomed PE Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Advanced Biomed's PE Ratio distribution charts can be found below:
* The bar in red indicates where Advanced Biomed's PE Ratio falls into.
Advanced Biomed Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Advanced Biomed's Earnings Per Share (Diluted) for the fiscal year that ended in Jun. 2025 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.76
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of $4.76 mean?
Advanced Biomed (ADVB) has a Earnings per Share (Diluted) of $4.76 as of Mar. 2026. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Advanced Biomed and its competitors. According to the industry distribution chart, Advanced Biomed ranks #157 out of 159 companies in the Medical Diagnostics & Research industry, placing it in the top 98.7%.
Is Advanced Biomed's Earnings per Share (Diluted) too high?
Advanced Biomed's current Earnings per Share (Diluted) is $4.76. The Medical Diagnostics & Research industry median Earnings per Share (Diluted) is 10.80. Advanced Biomed's value of $4.76 is 55.9% below this industry median. Based on the distribution chart, Advanced Biomed ranks #157 out of 159 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Advanced Biomed has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Advanced Biomed's Earnings per Share (Diluted) compare to MBAI and XWEL?
According to the Medical Diagnostics & Research industry distribution chart, Advanced Biomed ranks #157 out of 159 companies for Earnings per Share (Diluted). This places Advanced Biomed in the lower half of its industry. The industry median Earnings per Share (Diluted) is 10.80. Advanced Biomed's value of $4.76 is 55.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Medical Diagnostics & Research company?
The median Earnings per Share (Diluted) among Medical Diagnostics & Research companies is 10.80, based on 159 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Advanced Biomed's current Earnings per Share (Diluted) of $4.76 is 55.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Advanced Biomed and its competitors. For the Medical Diagnostics & Research industry, the median Earnings per Share (Diluted) is 10.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Advanced Biomed's current Earnings per Share (Diluted) is $4.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Advanced Biomed stock overvalued right now?
Advanced Biomed (ADVB) has a current Earnings per Share (Diluted) of $4.76. The current Earnings per Share (Diluted) is $4.76 and 55.9% below the Medical Diagnostics & Research industry median of 10.80. Advanced Biomed's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Advanced Biomed (ADVB), the current Earnings per Share (Diluted) is $4.76 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Advanced Biomed Inc operates through its subsidiaries and is mainly engaged in the research and development of various original microfluidic biochip technologies and the provision of tumor precision diagnosis and treatment technology applications. Through the joint application of semiconductor technology and biotechnology, it has developed various technologies and testing equipment for early screening and detection, diagnosis and staging, and treatment of cancer. Its devices: A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip, and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.
12GF Score
Get the complete analysis for ADVB
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADVB has been successfully added to your 
